Induction of a MHC class I-restricted, CD8 positive cytolytic T-cell response by chimeric HIV-1 virus-like particles in vivo: implications on HIV vaccine development - PubMed (original) (raw)

Affiliations

PMID: 7755506

Review

Induction of a MHC class I-restricted, CD8 positive cytolytic T-cell response by chimeric HIV-1 virus-like particles in vivo: implications on HIV vaccine development

R Wagner et al. Behring Inst Mitt. 1994 Dec.

Abstract

New insights into HIV-pathogenesis suggest that the cell mediated immune response might play a crucial role in controlling HIV infection by suppressing HIV-replication in CD4-positive cells by a lymphokine-like soluble factor and by killing HIV-infected cells via classical CTL mediated lysis. This type of a cellular immune response rather than an antibody response seems to be most promising to protect if not from infection, so at least from disease. Therefore rationally designed candidate vaccines should be capable of inducing a cell mediated immunity in addition to a humoral immune response. In order to avoid adverse side effects upon immunization, carefully selected antigens and epitopes should be presented in a favourable manner to the immune system. In previous experiments, we could demonstrate that the gag-polyprotein precursor, known to include a series of T-helper and CTL epitopes, assembles to highly immunogenic, complete noninfectious HIV-1 virus-like particles (VLP). Based on these VLP we developed a novel antigen presentation system, which allows the presentation of selected epitopes derived from HIV reading frames other than gag to the immune system. Alternatively complete derivatives of the HIV-1 external glycoprotein can be presented by the VLP. Immunological analysis of different VLP preparations in a BALB/c mouse model revealed the induction of a strong CTL response. The significance of these observations for future vaccine strategies is discussed.

PubMed Disclaimer

Cited by

VLP-factory™ and ADDomer© : Self-assembling Virus-Like Particle (VLP) Technologies for Multiple Protein and Peptide Epitope Display.
Sari-Ak D, Bufton J, Gupta K, Garzoni F, Fitzgerald D, Schaffitzel C, Berger I. Sari-Ak D, et al. Curr Protoc. 2021 Mar;1(3):e55. doi: 10.1002/cpz1.55. Curr Protoc. 2021. PMID: 33729713 Free PMC article.
Immunogenicity in Rabbits of Virus-Like Particles from a Contemporary Rabbit Haemorrhagic Disease Virus Type 2 (GI.2/RHDV2/b) Isolated in The Netherlands.
Miao Q, Qi R, Veldkamp L, Ijzer J, Kik ML, Zhu J, Tang A, Dong D, Shi Y, van Oers MM, Liu G, Pijlman GP. Miao Q, et al. Viruses. 2019 Jun 14;11(6):553. doi: 10.3390/v11060553. Viruses. 2019. PMID: 31207978 Free PMC article.
Virus like particle-based vaccines against emerging infectious disease viruses.
Liu J, Dai S, Wang M, Hu Z, Wang H, Deng F. Liu J, et al. Virol Sin. 2016 Aug;31(4):279-87. doi: 10.1007/s12250-016-3756-y. Epub 2016 Jul 11. Virol Sin. 2016. PMID: 27405928 Free PMC article. Review.
Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever.
Branco LM, Grove JN, Geske FJ, Boisen ML, Muncy IJ, Magliato SA, Henderson LA, Schoepp RJ, Cashman KA, Hensley LE, Garry RF. Branco LM, et al. Virol J. 2010 Oct 20;7:279. doi: 10.1186/1743-422X-7-279. Virol J. 2010. PMID: 20961433 Free PMC article.
Virus-like particles-universal molecular toolboxes.
Ludwig C, Wagner R. Ludwig C, et al. Curr Opin Biotechnol. 2007 Dec;18(6):537-45. doi: 10.1016/j.copbio.2007.10.013. Curr Opin Biotechnol. 2007. PMID: 18083549 Free PMC article. Review.

Induction of a MHC class I-restricted, CD8 positive cytolytic T-cell response by chimeric HIV-1 virus-like particles in vivo: implications on HIV vaccine development - PubMed (original) (raw)